bioAffinity Technologies has filed a notice of an exempt offering of securities to raise $1,302,084.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, bioAffinity Technologies is raising up to $1,302,084.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Maria Zannes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About bioAffinity Technologies
Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath Flow Cytometry for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. CyPath Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
To learn more about bioAffinity Technologies, visit http://bioaffinitytech.com/
bioAffinity Technologies Linkedin Page: https://www.linkedin.com/company/bioaffinitytechnologies/
Contact:
Maria Zannes, President and Chief Executive Officer
210-698-5334
https://www.linkedin.com/in/maria-zannes-32496815/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.